1. Medtech Insight
  2. >>Device Area
  3. >>Surgery

Paragonix Develops Devices To Reduce Transplantation Transport-Related Failure

 
• By Barnaby Pickering

Keeping organs designated for transplantation cool is vital to ensure procedure success. Medtech Insight spoke to Paragonix’s CEO, Lisa Anderson, to learn more.

Paragonix has developed a range of organ transportation devices to tackle the structural and logistical challenges surrounding organ transplantation.

So far, the Cambridge, MA-based company has developed devices for transporting human hearts, lungs, livers, kidneys and pancreases. It is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Surgery

Precise Bio Achieves Historic First 3D-Bioprinted Corneal Implant In Human, Part Of Early Trial

Medtech Insight spoke with Rambam Medical Center’s Michael Mimouni, who implanted the first 3D-bioprinted corneal graft in a human patient, about his hopes for Precise Bio’s approach. The patient is part of a Phase I trial evaluating PB-001 in patients with corneal edema.

Digital Health Roundup: BCIs Surge Ahead, Oura Eyes BP Clearance, AI Faces New Scrutiny

 
• By Marion Webb, Brian Bossetta, Elizabeth Orr, and Shubham Singh

Brain-computer interfaces advance toward trials and commercialization, Oura pushes for FDA-cleared blood pressure monitoring, and regulators weigh AI’s expanding role in mental health and diagnostics amid rising safety concerns.

BCI Maker INBRAIN Inks Deal With Microsoft To Explore Agentic AI Use For Monitoring Patients

 
• By Marion Webb

INBRAIN teamed up with Microsoft to apply agentic AI to analyze real-time brain data and eventually recommend programming like a “mini-neurologist,” said CEO Carolina Aguilar. It also seeks to enable scalable deployment of INBRAIN’s graphene-based technology and potential joined research.

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

More from Device Area

LDTs Aimed At Catching Cancers Early Hold Promise In Reducing Late-Stage Diagnoses, Study Shows

 
• By Brian Bossetta

A recent study demonstrates that certain types of blood-based tests that screen for multiple cancers at once have the potential to flip the script on cancer diagnoses, including some of the deadliest types.

Rarity Bioscience Sees Way Forward For superRCA Liquid Biopsy Platform, Despite Challenges

 
• By Barnaby Pickering

Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.

Abbott’s $21Bn Buyout Of Exact Sciences Paves Way To Fast-Growing Cancer Screening Market

 
• By Marion Webb

Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.